Synergistic effects of ATAD2 inhibitor with tamoxifen on ER-positive breast cancer cells
Conference Year
2023
Abstract
ATAD2 is a chromatin-associated protein with roles in DNA replication and transcription. ATAD2 is associated with poor breast cancer outcomes and is a possible therapeutic target in cancer, exploring drugs that inhibit ATAD2 function is important. ATAD2 has a bromodomain that recognizes acetylated lysine residues in histone proteins. Inhibitors that target bromodomains hold promise as anticancer drugs. Preliminary data revealed a decrease in cellular viability of breast cancer cells using ATAD2 inhibitor (BAY850). Ongoing and future studies aim to explore mechanism(s) of BAY850 by evaluating its effect on cells to outline its mechanisms of action in ER+ breast cancer cells.
Primary Faculty Mentor Name
Melissa Scheiber
Graduate Student Mentors
Hana Paculova
Status
Undergraduate
Student College
College of Nursing and Health Sciences
Program/Major
Medical Laboratory Science
Primary Research Category
Clinical
Synergistic effects of ATAD2 inhibitor with tamoxifen on ER-positive breast cancer cells
ATAD2 is a chromatin-associated protein with roles in DNA replication and transcription. ATAD2 is associated with poor breast cancer outcomes and is a possible therapeutic target in cancer, exploring drugs that inhibit ATAD2 function is important. ATAD2 has a bromodomain that recognizes acetylated lysine residues in histone proteins. Inhibitors that target bromodomains hold promise as anticancer drugs. Preliminary data revealed a decrease in cellular viability of breast cancer cells using ATAD2 inhibitor (BAY850). Ongoing and future studies aim to explore mechanism(s) of BAY850 by evaluating its effect on cells to outline its mechanisms of action in ER+ breast cancer cells.